Detalhe da pesquisa
1.
The differentiation and stress response factor XBP-1 drives multiple myeloma pathogenesis.
Cancer Cell
; 11(4): 349-60, 2007 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-17418411
2.
Bruton tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myeloma.
Blood
; 120(9): 1877-87, 2012 Aug 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-22689860
3.
The PTEN and INK4A/ARF tumor suppressors maintain myelolymphoid homeostasis and cooperate to constrain histiocytic sarcoma development in humans.
Cancer Cell
; 9(5): 379-90, 2006 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-16697958
4.
High-resolution genomic profiles define distinct clinico-pathogenetic subgroups of multiple myeloma patients.
Cancer Cell
; 9(4): 313-25, 2006 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-16616336
5.
TRIM13 (RFP2) downregulation decreases tumour cell growth in multiple myeloma through inhibition of NF Kappa B pathway and proteasome activity.
Br J Haematol
; 162(2): 210-20, 2013 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-23647456
6.
A proto-oncogene BCL6 is up-regulated in the bone marrow microenvironment in multiple myeloma cells.
Blood
; 115(18): 3772-5, 2010 May 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-20228272
7.
MicroRNAs 15a/16-1 function as tumor suppressor genes in multiple myeloma.
Blood
; 2010 Oct 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-20962322
8.
Aurora kinase A is a target of Wnt/beta-catenin involved in multiple myeloma disease progression.
Blood
; 114(13): 2699-708, 2009 Sep 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-19652203
9.
MFG-E8-mediated uptake of apoptotic cells by APCs links the pro- and antiinflammatory activities of GM-CSF.
J Clin Invest
; 117(7): 1902-13, 2007 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-17557120
10.
Targeting NF-kappaB in Waldenstrom macroglobulinemia.
Blood
; 111(10): 5068-77, 2008 May 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-18334673
11.
Expression of p16Ink4a compensates for p18Ink4c loss in cyclin-dependent kinase 4/6-dependent tumors and tissues.
Cancer Res
; 67(10): 4732-41, 2007 May 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-17510401
12.
Mouse models of human myeloma.
Hematol Oncol Clin North Am
; 21(6): 1051-69, viii, 2007 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-17996588
13.
In vitro and in vivo activity of the maytansinoid immunoconjugate huN901-N2'-deacetyl-N2'-(3-mercapto-1-oxopropyl)-maytansine against CD56+ multiple myeloma cells.
Cancer Res
; 64(13): 4629-36, 2004 Jul 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-15231675
14.
Multiplex flow cytometry barcoding and antibody arrays identify surface antigen profiles of primary and metastatic colon cancer cell lines.
PLoS One
; 8(1): e53015, 2013.
Artigo
em Inglês
| MEDLINE | ID: mdl-23308131
15.
BCL9 promotes tumor progression by conferring enhanced proliferative, metastatic, and angiogenic properties to cancer cells.
Cancer Res
; 69(19): 7577-86, 2009 Oct 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-19738061
16.
Milk fat globule EGF-8 promotes melanoma progression through coordinated Akt and twist signaling in the tumor microenvironment.
Cancer Res
; 68(21): 8889-98, 2008 Nov 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-18974133
17.
Ink4a/Arf tumor suppressor does not modulate the degenerative conditions or tumor spectrum of the telomerase-deficient mouse.
Proc Natl Acad Sci U S A
; 104(10): 3931-6, 2007 Mar 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-17360455
18.
FoxOs are lineage-restricted redundant tumor suppressors and regulate endothelial cell homeostasis.
Cell
; 128(2): 309-23, 2007 Jan 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-17254969
19.
Targeting the beta-catenin/TCF transcriptional complex in the treatment of multiple myeloma.
Proc Natl Acad Sci U S A
; 104(18): 7516-21, 2007 May 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-17452641
20.
A clinically relevant SCID-hu in vivo model of human multiple myeloma.
Blood
; 106(2): 713-6, 2005 Jul 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-15817674